Hyphens Pharma Pte. Ltd., a subsidiary of Hyphens Pharma International Limited, has launched Winlevi® (clascoterone) cream 1% in Singapore and Malaysia, marking its first entry into Southeast Asia. This innovative topical acne treatment is now available via prescription through clinics and hospitals in these countries, with plans for further rollout across the region.
Winlevi® is the first new class of molecule in acne treatment in over 40 years, targeting the androgen-sebum pathway directly within the skin. Its active ingredient, clascoterone, is the first commercially available topical androgen receptor inhibitor for acne, reducing sebum production and inflammation without systemic anti-androgen side effects. This makes it a safe option for both male and female patients.
The launch is part of Hyphens Pharma’s strategic expansion in dermatology, a core focus area that includes treatments for acne, atopic dermatitis, hyperpigmentation, and hair loss. The company has secured an exclusive licence and supply agreement with Cassiopea S.p.A., a subsidiary of Cosmo Pharmaceuticals, covering Winlevi® and its future product extensions across 10 Southeast Asian countries.
Lim See Wah, Executive Chairman and CEO of Hyphens Pharma, stated, “We’re proud to be the first to introduce Winlevi® to Southeast Asia. Acne affects millions in the region, yet for decades, patients have had limited treatment options. This launch marks a significant advancement in acne care.”
Winlevi® has already been approved and launched in several countries, including the US, where it has become the most prescribed branded topical acne treatment since its 2021 debut. The introduction of Winlevi® in Southeast Asia represents a significant step in addressing unmet needs in acne care, with a multinational Advisory Board of dermatologists supporting its integration into clinical practice.
“`
